260 related articles for article (PubMed ID: 12124172)
21. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Walters DK; Stoffregen EP; Heinrich MC; Deininger MW; Druker BJ
Blood; 2005 Apr; 105(7):2952-4. PubMed ID: 15585651
[TBL] [Abstract][Full Text] [Related]
22. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
25. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
26. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
27. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
[TBL] [Abstract][Full Text] [Related]
28. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
[TBL] [Abstract][Full Text] [Related]
29. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
30. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
31. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
32. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
33. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
34. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
35. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
36. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG
Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
[TBL] [Abstract][Full Text] [Related]
38. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Levis M; Tse KF; Smith BD; Garrett E; Small D
Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
[TBL] [Abstract][Full Text] [Related]
39. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
